December 21, 2018 07:38 AM EST

Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege